Significant advances in the outcome of patients with malignant blood diseases took place over the past decades. Although adopting further breakthroughs in medical sciences, clinicians also continue to optimize the delivery of increasingly complex treatment strategies, with growing attention being paid to patients' quality of life and health care systems sustainability.
For some specific subsets of diseases such as poor-prognosis or relapsed non-Hodgkin lymphomas, Hodgkin diseases or multiple myelomas, the treatment protocol includes high-dose chemotherapy supported with autologous hematopoietic cell transplantation (ASCT). This however can be envisaged only when mobilized PBSC collection and cryopreservation is successful. 1 The addition of plerixafor-an inhibitor of the interaction between stromal cell-derived factor 1 (SDF-1/CXCL12) and its receptor CXCR4-to G-CSF enhances hematopoietic stem cell (HSC) mobilization. [1] [2] [3] When patients are identified as being poor mobilizers, sub-cutaneous plerixafor can be introduced on top of G-CSF-replete mobilization regimen (including or not chemomobilization), either immediately ('pre-emptive' or 'on-time' administration), or as part of a remobilization attempt following a 'washout' period. In keeping with the approved European Summary of Product Characteristics (SmPC), 4 the recommended dose of plerixafor (0.24 mg/kg body weight/day) should be administered by SC injection 6-11 h before initiation of each apheresis following 4 day pre-treatment with G-CSF.
Today, as a combined consequence of patients' wishes, reorganization of health care provision, and the need to reduce the economic burden of cancer care, many treatments are no longer delivered in an inpatient setting, but in an outpatient setting or even as homecare. Paradoxically, although hematopoietic growth factors and plerixafor that are commonly used for stem cell mobilization are entailed with much less severe toxicities than cytotoxic agents, there are few data available on the feasibility of outpatient plerixafor administration. This is in part due to the complex scheduling of drug administration and apheresis execution, but potentially also because of the more subjective perception that an expensive and relatively rarely used medication may deserve special attention. As a consequence, the demonstration that efficient mobilization and collection can be equally achieved after outpatient or home administration of plerixafor is missing. The question is especially relevant, as there is an increasing proportion of poor mobilizers who receive 'pre-emptive' or 'on time' plerixafor to compensate for insufficient mobilization after proper administration of G-CSF, and inpatient hospitalization is difficult to organize within such a short time at many institutions.
In 2015, the results of a nationwide postmarketing survey on the routine use of plerixafor in daily clinical practice rather than in clinical trials, confirmed the efficacy of this mobilization regimen, with plerixafor being used for poor mobilizers in compliance with terms of the European marketing authorization. 5 Furthermore, plerixafor was well tolerated, with few declared side effects (mostly of digestive nature); a significant proportion of treated patients received the medication outside of the hospital.
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We here report an additional analysis of the OSMOZ registry data, exploring the reported practical modalities of plerixafor administration (inpatient, outpatient setting or homecare, as authorized by the SmPC 4 ) and whether or not this has clinical consequences, particularly with regard to the quality of the collected graft. As recommended, management of the risk of anaphylactic shock was managed by informing and observing patients for signs and symptoms of hypersensitivity during and after plerixafor administration for at least 30 min and until clinically stable. No such adverse event was reported in this survey.
Thirty three out of 38 French transplant centers-representing 86.8% of active French collection facilities-reported on 262 patients. In sixty-eight percent (N = 179) of cases, administration of plerixafor was performed as part of an inpatient stay; in 3% of cases, (N = 8 pts) plerixafor was administered while the patient was in the outpatient clinic; in 29% of cases (N = 75 pts), patients received plerixafor at home, following discharge from the apheresis facility, and awaiting readmission the next day. Patients' characteristics at the time of plerixafor injection were similar in the 3 groups: age, gender, weight, initial diagnosis, time from diagnosis to mobilization, disease status, previous chemotherapies, number of previous lines, previous radiotherapy, number of lines of radiotherapy and cumulative dose, previous stem cell transplantations, chemo-mobilization, G-CSF administration. Thus, no specific patient profile appears to favor one particular mobilization management environment over another. However, the center of origin varied significantly, reflecting procedural variations in programs organizations, one of which being the choice of a modality for plerixafor administration.
Consistent with this observation, compliance with the '6-11 h delay between plerixafor administration and initiation of apheresis' rule varied, 4 depending on whether administration of plerixafor was inpatient, outpatient or at home. Indeed, 87.3% of inpatient treated individuals received plerixafor 6-11 h before apheresis, whilst the delay was shorter (o 6 h) for 75% (35-97%) of patients treated in the outpatient clinic; as only a low number of patients were treated in the outpatient clinic, the possibility to start apheresis early after plerixafor administration deserves further investigations. Conversely, the delay was longer for homecare patients, with nearly 30% of them initiating apheresis more than 11 h after plerixafor administration. The complexity in reorganizing the patient treatment and readmission, and the apheresis facility activities most likely explains the observed trend (Table 1) .
The threshold value of 20 peripheral blood (PB) CD34 + cells/μL was achieved in 97.3% of the patients after plerixafor injection and before apheresis. The apheresis collection target of CD34 + cells ⩾ 2.0 × 106 PB CD34 + cells/kg required to undergo ASCT, was reached in 91.8% of the patients, with no significant difference observed across the three subsets with different modalities for plerixafor administration (inpatient 91.4%, outpatient 100% and homecare 91.8%; Table 2 ).
Thus, even though the timing between plerixafor administration and apheresis does not fully comply with the EU marketing authorization and the SmPC terms 4 or with the FDA Highlights of prescribing information, 6 our data suggest that home administration does not negatively affect the ability to collect an acceptable graft, and thus does not compromise the possibility to proceed to high-dose chemotherapy supported with autologous ASCT.
On the basis of clinical trial results, the European Authorities recommended that poor mobilizers receive plerixafor injection within 6-11 h before apheresis. 4 US Authorities do not restrict recommendations to 'patients who mobilize poorly', however, target the same categories of diseases, and express recommendations for plerixafor injection in a slightly different wording: '~11 h before the beginning of apheresis '. 6 In 2003, Liles et al. 7 published results on healthy volunteers treated with plerixafor, with doses ranging from 80 μg/kg to 240 μg/kg; At 240 μg/kg dosing, PB CD34 + cell counts remained above 20/μL, from nearly 3 h to more than 12 h after plerixafor administration, with a peak at 9 h. The same authors reported the PB CD34 + cell kinetics of three additional healthy donors, in which a sustained elevation in the PB CD34 + cell count was observed from 4 to 18 h following the administration of plerixafor, with a peak value of 168.0 × 10 6 ± 45.0 × 10 6 CD34 + cells/L at 14 h. 8 In 2013, Lefrere et al. 9 sequentially surveyed PB CD34 + cell counts every 3 h in 'poor mobilizer patients', and showed them to reach the threshold value as early as 3 h after plerixafor injection, starting to decline at 8-12 h; thus apheresis may not always be performed at the optimal time, although early monitoring of PB CD34
+ cell counts to decide on optimal timing for initiation of apheresis is likely to be impractical at most hospitals and apheresis facilities.
Such kinetics may in part be explained by biological activities of SDF-1α and plerixafor, 10 none of which induce HSC proliferation. Even when stimulated to proliferate, 6 h may not be sufficient to produce an expansion of HSC. In mobilization regimens that are used in clinical practice, G-CSF most likely stimulates HSC proliferation, which are then released from the marrow into the circulation, a response increased by plerixafor addition.
The purpose of this sub-analysis of the OSMOZ survey was to determine whether the three different plerixafor administration modalities (inpatient ward, outpatient clinic and home administration) and, therefore, the timing from plerixafor administration to apheresis, are equivalent and compatible with a successful harvest of CD34 + cells, making it possible to proceed with an ASCT. The findings of this sub-analysis of the Osmoz survey show that although some trend of plerixafor administration timing overlap exists in real life, it is probably linked to local logistical difficulties in co-ordinating the plerixafor mobilization regimen process with apheresis execution, and does not appear to have an impact on the patient's chance to benefit from ASCT.
These observations support further changes in routine clinical practices and improvements in patient care management modalities that take advantage of outpatient or home administration; this may lead to improvement in patients' quality of life and cost reductions, whilst maintaining the odds of favorable clinical outcome.
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